End-stage renal disease (ESRD) Urological and Genital Diseases Chronic kidney disease, stage 5
Conditions
Interventions
In Singapore, patients have to attend a one-hour face-to-face haemodialysis education provided by the physicians before their first haemodialysis. In this one hour routine care, the physician will inf
Sponsors
National Kidney Foundation of Singapore
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with ESRD and undergoing haemodialysis 2. Age 21 years old and above 3. Able to speak, read and write either English or Mandarin
Exclusion criteria
Exclusion criteria: 1. Cognitive impairment and/or mental disorder identified from their medical records 2. Vision and hearing impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dialysis Specific Self-efficacy Scale (DSSS) (Appendix VI) will be used to measure ESRD patients’ self-efficacy in relation to their self-management of dialysis including fluid and diet management (Griva et al., 2011). The DSSS is an 8-item questionnaire using a 10-point Likert scale ranging from 1 to 10 (with 1 representing “not all confident” and 10 representing “totally confident”). The higher scores indicate higher self-efficacy. Outcomes will be measured at baseline, 1- and 3- and 6-month follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcomes will be measured at baseline, 1- and 3- and 6-month follow-up: 1. Patients’ demographic data (e.g. age, gender, ethnicity, education) and clinical data (e.g. type, period and frequency of haemodialysis, blood pressure etc) will be collected at baseline. 2. Kidney Disease Quality of Life 36 (KDQoL-36) (Appendix VII) will be used to measure the quality of life of patients with ESRD and haemodialysis. The KDQoL-36 is a self-report measure developed for individuals with kidney disease and those on dialysis, which includes contents of symptoms, effects of kidney disease on daily life, burden of kidney disease, cognitive function, work status, sexual function, quality of social interaction, and sleep. KDQOL-36 have been validated with a Cronbach’s alpha ranging from 0.72 to 0.95 in numerous studies conducted in Asia and Overseas on patients with chronic kidney disease, end-stage renal disease and dialysis (Joshi et al., 2010). 3. Hospital Anxiety and Depression Scale (HADS) (Appendix VIII) will be used to measure the psychological wellbeing of the participants. This instrument has been widely used in different contexts for different age groups of patients. HADS has been found to perform well in assessing the symptom severity and cases of anxiety disorders and depression in both the general population and the somatic, psychiatric and primary care patients (Bjelland, Dahl, Haug, & Neckelmann, 2002). A review study by Bjelland et al. (2002) reported that Cronbach’s alpha for HADS-A varied from .68 to .93 (mean .83) and for HADS-D from .67 to .90 (mean .82). The sensitivity and specificity for both HADS-A and HADS-D were approximately 0.80. 4. Renal Adherence Attitudes Questionnaire (RAAQ) (Appendix IX) will be used to assess patients’ treatment adherence attitude (Griva et al., 2011). RAAQ is a 26-item questionnaire to measure general attitudes toward compliance including patients’ attitudes toward social restrictions, well-being, self-care/support, and accepta | — |
Countries
Singapore
Outcome results
None listed